NCT04520022View on ClinicalTrials.gov

Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 13, 2016

Primary Completion Date

January 10, 2020

Study Completion Date

January 10, 2020

Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
DRUG

Human Umbilical Cord Blood-derived Mesenchymal Stem Cells

3.0 x 106 cells/kg, IV, Total of 3 doses every 2weeks

Trial Locations (1)

Unknown

GangnamSeverance Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

lead

Gangnam Severance Hospital

OTHER

NCT04520022 - Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB | Biotech Hunter | Biotech Hunter